JP2023533963A5 - - Google Patents

Info

Publication number
JP2023533963A5
JP2023533963A5 JP2023501015A JP2023501015A JP2023533963A5 JP 2023533963 A5 JP2023533963 A5 JP 2023533963A5 JP 2023501015 A JP2023501015 A JP 2023501015A JP 2023501015 A JP2023501015 A JP 2023501015A JP 2023533963 A5 JP2023533963 A5 JP 2023533963A5
Authority
JP
Japan
Application number
JP2023501015A
Other languages
Japanese (ja)
Other versions
JPWO2022010988A5 (https=
JP2023533963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040648 external-priority patent/WO2022010988A1/en
Publication of JP2023533963A publication Critical patent/JP2023533963A/ja
Publication of JP2023533963A5 publication Critical patent/JP2023533963A5/ja
Publication of JPWO2022010988A5 publication Critical patent/JPWO2022010988A5/ja
Pending legal-status Critical Current

Links

JP2023501015A 2020-07-08 2021-07-07 抗ctla-4抗体を含む安定化製剤 Pending JP2023533963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049540P 2020-07-08 2020-07-08
US63/049,540 2020-07-08
PCT/US2021/040648 WO2022010988A1 (en) 2020-07-08 2021-07-07 Stabilized formulations containing anti-ctla-4 antibodies

Publications (3)

Publication Number Publication Date
JP2023533963A JP2023533963A (ja) 2023-08-07
JP2023533963A5 true JP2023533963A5 (https=) 2024-07-16
JPWO2022010988A5 JPWO2022010988A5 (https=) 2024-07-16

Family

ID=77207237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501015A Pending JP2023533963A (ja) 2020-07-08 2021-07-07 抗ctla-4抗体を含む安定化製剤

Country Status (10)

Country Link
US (1) US20220031843A1 (https=)
EP (1) EP4178983A1 (https=)
JP (1) JP2023533963A (https=)
KR (1) KR20230035595A (https=)
CN (1) CN115812080A (https=)
AU (1) AU2021305093A1 (https=)
CA (1) CA3185091A1 (https=)
IL (1) IL299152A (https=)
MX (1) MX2022016218A (https=)
WO (1) WO2022010988A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009558A (es) * 2020-02-04 2022-09-09 Regeneron Pharma Contenido de humedad residual objetivo para farmaco liofilizado.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112013008366B1 (pt) * 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
EP2633874A1 (en) * 2012-03-02 2013-09-04 Sanofi-Aventis Deutschland GmbH Fixed-dose medicament delivery device
AR092325A1 (es) * 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
EP3856246A4 (en) * 2018-09-24 2022-07-20 Janssen Biotech, Inc. METHOD FOR ENSURING SAFE ADMINISTRATION OF ANTI-CD154 ANTIBODY
CN114793422A (zh) * 2019-12-25 2022-07-26 百奥泰生物制药股份有限公司 抗ctla-4单克隆抗体及其制备方法与应用

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)